Psoriasis Market Report 2026

Psoriasis Market Overview

• Psoriasis market size has reached to $28.93 billion in 2025 • Expected to grow to $44.79 billion in 2030 at a compound annual growth rate (CAGR) of 9.3% • Growth Driver: Rising Prevalence Of Psoriasis Patients Driving Market Growth Due To Increasing Demand For Advanced Biologic And Targeted Treatment Therapies • Market Trend: Embedding Autoinjector Delivery Systems For Biosimilar Ustekinumab Therapies • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Psoriasis Market?

Psoriasis refers to a skin condition that typically affects the knees, elbows, trunk, and scalp and results with a rash with itchy, scaly spots. The primary contributing factor may be an immune system issue wherein infection-fighting cells unintentionally kill healthy skin cells. The main classes of drugs in psoriasis are interleukin inhibitors, corticosteroids, anti-inflammatory, and tumor necrosis factor inhibitors. Corticosteroids are a group of steroid hormones generated by vertebrates' adrenal cortex and are also synthetic equivalents of these hormones. The different types of drugs include small molecules and biologics and involve various disease indications such as plaque psoriasis, nail psoriasis, guttate psoriasis, pustular psoriasis, and erythrodermic psoriasis. The several routes of administration include oral, topical, injectable, and distributed through hospitals, retail pharmacies, and e-commerce.

What Is The Psoriasis Market Growth Forecast?

The psoriasis market size is expected to see strong growth in the next few years. It will grow to $44.79 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to growth in biologic drug approvals, rising patient awareness, increasing diagnosis of severe psoriasis, expansion of specialty clinics, higher healthcare spending on dermatology. Major trends in the forecast period include rising adoption of biologic therapies for psoriasis, increasing long-term disease management approaches, growing demand for injectable psoriasis treatments, expansion of hospital and specialty dermatology care, increased focus on moderate-to-severe psoriasis.

Global Psoriasis Market Segmentation

1) By Drug class: Interleukin Inhibitors, Corticosteroids, Anti-Inflammatory, Tumor Necrosis Factor Inhibitor 2) By Drug Types: Small molecules, Biologics   3) By Disease Indication: Plaque Psoriasis, Nail Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis 4) By Route Of Administration: Oral, Topical, Injectable 5) By Distribution Channel: Hospitals, Retail Pharmacies, E-Commerce Subsegments: 1) By Interleukin Inhibitors: IL-12/23 Inhibitors (Ustekinumab), IL-17 Inhibitors (Secukinumab, Ixekizumab) 2) By Corticosteroids: Topical Corticosteroids (Hydrocortisone, Betamethasone), Systemic Corticosteroids (Prednisone) 3) By Anti-Inflammatory: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 4) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade)

What Is The Driver Of The Psoriasis Market?

The rise in the prevalence of psoriasis patients is expected to propel the growth of the psoriasis market going forward. Psoriasis is a chronic autoimmune skin disorder characterized by rapid skin cell buildup leading to inflammation, scaling, and discomfort, often requiring continuous medical treatment and monitoring. The rise in psoriasis patients is due to an overactive immune system mistakenly attacking healthy skin cells, often triggered or exacerbated by environmental factors such as infections, stress, or skin trauma. The growing prevalence of psoriasis supports the psoriasis market by increasing demand for biologics, topical agents, immunomodulators, and phototherapy solutions designed to reduce flare-ups, improve symptoms, and enhance patient quality of life. For instance, in 2025, according to Global Psoriasis Atlas, a UK-based research organization focused on psoriasis, an estimated 43 million people have psoriasis based on physician and dermatologist diagnoses, while approximately 102 million people report having psoriasis based on self-reported cases. Therefore, the rise in the prevalence of psoriasis patients is driving the growth of the psoriasis industry.

Key Players In The Global Psoriasis Market

Major companies operating in the psoriasis market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Amgen Inc., Merck & Co. Inc., Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Union Chimique Belge SA, Sun Pharmaceutical Industries Ltd., Almirall SA, Bausch Health Companies Inc., Biogen Inc., Biocon Biopharmaceuticals Pvt. Ltd., Celltrion Inc., Dr.Reddy's Laboratories Inc., Arcutis Biotherapeutics Inc., Bayer AG, Bristol Myers Squibb Co., Galderma SA, GlaxoSmithKline Plc, Incyte Pharmaceuticals Corp., LEO Pharmacy

Global Psoriasis Market Trends and Insights

Major companies operating in the psoriasis market are focusing on product innovation and formulation such as autoinjector delivery systems for biosimilars, to improve patient adherence, convenience, and treatment outcomes while maintaining the efficacy and safety profiles of reference biologics. These solutions enable self-administration, reduce injection discomfort, and support broader adoption of biosimilar therapies across Europe and other markets. For instance, in May 2025, Sandoz, a Switzerland-based biopharmaceutical company, launched Pyzchiva autoinjector, the first commercially available autoinjector for ustekinumab biosimilars in Europe. The Pyzchiva autoinjector is designed to provide simple, accurate, and patient-friendly administration of biosimilar ustekinumab, supporting improved adherence for chronic psoriasis management. This launch highlights a market trend toward enhancing patient-centric delivery options for biologics and biosimilars, increasing accessibility and convenience for individuals living with psoriasis.

What Are Latest Mergers And Acquisitions In The Psoriasis Market?

In October 2024, Organon, a US-based healthcare company, acquired Dermavant Sciences, Inc., for an undisclosed amount. Through this acquisition, Organon aims to enhance its dermatologic therapy portfolio by integrating Dermavant’s innovative treatments, including VTAMA, to address patients with psoriasis and other chronic skin conditions, thereby expanding its presence in the dermatology market. Dermavant Sciences, Inc. is a US-based pharmaceutical company specializing in innovative dermatologic therapies with a strong track record in clinical development for psoriasis and other skin disorders.

Regional Insights

North America was the largest region in the psoriasis market in 2025. Middle East is expected to be the fastest-growing region in the psoriasis market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Psoriasis Market?

The psoriasis market consists of sales of Methotrexate, Ciclosporin, and Acitretin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Psoriasis Market Report 2026?

The psoriasis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the psoriasis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.